Caris Life Sciences, Inc. Common Stock (CAI)vsJohnson & Johnson (JNJ)
CAI
Caris Life Sciences, Inc. Common Stock
$15.59
0.00%
HEALTHCARE · Cap: $4.66B
JNJ
Johnson & Johnson
$255.88
-3.63%
HEALTHCARE · Cap: $615.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 10694% more annual revenue ($97.93B vs $907.29M). JNJ leads profitability with a 21.5% profit margin vs 3.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).
CAI
Hold44
out of 100
Grade: D
JNJ
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 78.8% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of 5.7% — below average capital efficiency
3.8% margin — thin
Operating margin of 2.4%
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CAI
The strongest argument for CAI centers on Revenue Growth. Revenue growth of 78.8% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bear Case : CAI
The primary concerns for CAI are EPS Growth, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CAI profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
CAI is growing revenue faster at 78.8% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (57/100 vs 44/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caris Life Sciences, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?